Dolasetron



Dolasetron
Systematic (IUPAC) name
(3R)-10-oxo-8-azatricyclo[5.3.1.03,8]undec-5-yl 1H-indole-3-carboxylate
Identifiers
CAS number 115956-12-2
ATC code A04AA04
PubChem 60654
DrugBank APRD00518
Chemical data
O3 
Mol. mass 324.374 g/mol
Pharmacokinetic data
Bioavailability  ?
Protein binding 69 to 77%
Metabolism  ?
Half life 8.1 hours
Excretion  ?
Therapeutic considerations
Pregnancy cat.

?

Legal status
Routes  ?

Dolasetron (trade name Anzemet) is a muscarinic receptors.

Dolasetron breaks down slowly, staying in the body for a long time. One dose usually lasts 4 to 9 hours and is usually administered once or twice daily. This drug is removed from the body by the liver and kidneys.

Clinical uses

  • Chemotherapy-induced nausea and vomiting
    • 5-HT3 receptor antagonists are the primary drugs used to treat and prevent chemotherapy-induced nausea and vomiting. Many times they are given intravenously about 30 minutes before beginning therapy.
  • Post-operative and post-radiation nausea and vomiting
  • Is a possible therapy for nausea and vomiting due to acute or chronic medical illness or acute gastroenteritis

Adverse effects

Dolasetron is a well-tolerated drug with few cytochrome P450 system and it has little effect on the metabolism of other drugs broken down by this system.

References

  • Katzung, Bertram G. Basic and Clinical Pharmacology, 9th ed. (2004). ISBN 0-07-141092-9


 
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Dolasetron". A list of authors is available in Wikipedia.